CRANFORD, N.J., Oct. 7, 2025 /PRNewswire/ -- Citius Oncology, Inc. (CTOR) ("Citius Oncology" or the "Company"), a specialty biopharmaceutical company focused on the development and commercialization ...
Supports capital-efficient expansion of the SLS009 clinical program into frontline AML, enabling broader U.S. and European patient enrollment U.S. enrollment evaluating SLS009 in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback